GPC3 positive
GPC3 expression that helps confirm tumour origin and is being studied as a therapy target in liver cancer.
Parent marker: GPC3
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
GPC3 is often found in hepatocellular carcinoma. This marker is used to support diagnosis and as a target for therapeutic research.
How this finding appears in a report
Assessed through immunohistochemistry on tumor tissue.
When therapy stops working
Therapies targeting GPC3 are still in the clinical research phase.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: GPC3
GPC3 expression helps confirm tumor origin in doubtful cases and is a target for therapeutic research, including cellular therapy. Some of the approaches are still in the clinical research stage.
A negative result does not always mean absent
Summary
- Gen
- GPC3
- Variant
- GPC3 expression positive
- Alteration type
- Overexpression
- Discussed in
- Liver Cancer
- Updated
- 2026-09-10
Other names in reports
GPC3+
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- GPC3
Biomarker
Reason: Related through a biomarker
- Liver Cancer
Cancer type
Reason: Related to this page
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.